Compounds > 5-(3-methyl-1-triazeno)imidazole-4-carboxamide
Page last updated: 2024-08-25

5-(3-methyl-1-triazeno)imidazole-4-carboxamide and Brain Neoplasms

5-(3-methyl-1-triazeno)imidazole-4-carboxamide has been researched along with Brain Neoplasms in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fouladi, M; Gajjar, A; Heideman, RL; Kirstein, MN; Nair, G; Panetta, JC; Stewart, CF; Wilkinson, M1
Adachi, J; Aoki, T; Matsutani, M; Mishima, K; Mizutani, T; Nishikawa, R; Nojima, K1
Brent, TP; Friedman, HS; Houghton, PJ; Kirstein, MN; Middlemas, DS; Poquette, C; Stewart, CF1
Brent, TP; Cheshire, PJ; Friedman, HS; Houghton, PJ; Kirstein, MN; Poquette, CA; Richmond, LB; Stewart, CF; Tan, M1

Trials

1 trial(s) available for 5-(3-methyl-1-triazeno)imidazole-4-carboxamide and Brain Neoplasms

ArticleYear
Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:6

    Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Biological Availability; Body Surface Area; Brain Neoplasms; Child; Child, Preschool; Chromatography, High Pressure Liquid; Dacarbazine; Female; Humans; Infant; Linear Models; Male; Metabolic Clearance Rate; Reproducibility of Results; Temozolomide

2003

Other Studies

3 other study(ies) available for 5-(3-methyl-1-triazeno)imidazole-4-carboxamide and Brain Neoplasms

ArticleYear
Pharmacokinetic study of temozolomide on a daily-for-5-days schedule in Japanese patients with relapsed malignant gliomas: first study in Asians.
    International journal of clinical oncology, 2007, Volume: 12, Issue:5

    Topics: Administration, Oral; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Asian People; Brain Neoplasms; Dacarbazine; Drug Administration Schedule; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Temozolomide; White People

2007
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Brain Neoplasms; Carrier Proteins; Cell Division; Child; Dacarbazine; DNA Repair; DNA-Binding Proteins; Female; Humans; Mice; Mice, Inbred CBA; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Neuroblastoma; Nuclear Proteins; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Proto-Oncogene Proteins; Rhabdomyosarcoma; Temozolomide; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53

2000
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:10

    Topics: Administration, Oral; Alkylating Agents; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Brain Neoplasms; Camptothecin; Dacarbazine; DNA Repair; Female; Glioblastoma; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Neuroblastoma; O(6)-Methylguanine-DNA Methyltransferase; Phenotype; Rhabdomyosarcoma; Temozolomide; Time Factors

2000